Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-07-29 | New | $13,555,109 | $13,555,109 | Equity Only | 06b | SEC link |
| 2024-06-25 | New | $2,400,000 | $2,400,000 | Debt Only | 06b | SEC link |
| 2023-11-27 | New | $2,000,000 | $2,000,000 | Debt Only | 06b | SEC link |
| 2022-01-13 | New | $2,800,000 | $2,800,000 | Debt Only | 06b | SEC link |
| 2021-05-06 | New | $3,176,754 | $3,176,754 | Equity Only | 06b | SEC link |
| 2020-03-05 | New | $1,100,000 | $1,100,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Thomas Finn | Director |
| Meyer Frucher | Director |
| Bruce Halpryn | Director, Executive |
| Robert Johnson | Director |
| Samuel Lee | Director, Executive |
| Kenneth Morand | Director |
| Joseph Nolan | Director |
| Neel Patel | Director |